Cassava’s Shares Plunge as Alzheimer’s Drug Fails Phase III

Cassava Sciences has revealed the late-stage clinical failure of controversial Alzheimer’s drug simulfilam. The company had pledged to share the results whether “good, bad or ambiguous.”